Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac allograft vasculopathy: an update.

Ilke Sipahi1, Randall C Starling

  • 1Kaufman Center for Heart Failure, Cleveland, OH 44195, USA.

Heart Failure Clinics
|June 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of the Larissa Heart Failure Risk Score: Predictive Value in 9207 Patients Hospitalized for Heart Failure from a Single Center.

Journal of personalized medicine·2023
Same author

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.

European journal of heart failure·2023
Same author

The utilization and impact of cardiovascular specialists on guideline-directed medical scores: An analysis of a diverse, multi-state, electronic health record-based registry.

European journal of heart failure·2023
Same author

Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of <i>CDCP1</i> and Cardiac Fibrosis.

Circulation research·2023
Same author

Sex Differences in Myocardial Histology, Gene Expression, and Myocardial Recovery in Recent-Onset Cardiomyopathy.

JACC. Heart failure·2023
Same author

ACE inhibitors and the risk of lung cancer-is there causality?

British journal of cancer·2023

Cardiac allograft vasculopathy (CAV) significantly impacts heart transplant survival. Aggressive management of risk factors, statin use, and further research into mTOR inhibitors and intravascular ultrasound are crucial for improving patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Transplantation Immunology
  • Vascular Biology

Background:

  • Cardiac allograft vasculopathy (CAV) is a primary cause of long-term graft failure in heart transplantation.
  • Modifiable risk factors including obesity, diabetes, and hypertension are associated with CAV development.
  • Current management strategies require further refinement to improve long-term transplant recipient survival.

Purpose of the Study:

  • To review current understanding and management strategies for cardiac allograft vasculopathy (CAV).
  • To highlight the role of risk factor modification, statins, and emerging therapies in preventing CAV.
  • To emphasize the diagnostic and therapeutic potential of intravascular ultrasound in managing CAV.

Main Methods:

  • Review of existing literature on cardiac allograft vasculopathy.

Related Experiment Videos

  • Analysis of the role of risk factors (obesity, diabetes, hypertension) in CAV.
  • Evaluation of pharmacological interventions, including statins and mammalian target of rapamycin (mTOR) inhibitors.
  • Assessment of intravascular ultrasound (IVUS) as a diagnostic and prognostic tool.

    • Main Results:

    • Aggressive management of risk factors like obesity, diabetes, and hypertension is recommended.
    • Universal statin therapy is advised for all heart transplant recipients.
    • Clinical trials are necessary to determine the efficacy of mTOR inhibitors in preventing CAV.
    • Intravascular ultrasound shows promise as a surrogate marker for tailoring CAV management.

    Conclusions:

    • Improved understanding of CAV pathogenesis is essential for developing targeted preventive therapies.
    • Continued research into native atherosclerosis and vascular biology may yield future therapeutic breakthroughs.
    • A multi-faceted approach involving risk factor control, pharmacotherapy, and advanced imaging is key to improving outcomes in heart transplant recipients.